Market Access
What You Need to Know About the Trump Administration’s Final Rule on Transparency in Coverage
In a continued push for increasing price transparency in healthcare, the Trump administration recently ...
340B Cuts Could Impact Access to Specialty Drugs
For more than 25 years, the 340B Drug Pricing Program1 has helped safety-net facilities ...
Can “Risk-Sharing” Agreements Enable Fast Access to COVID-19 Vaccines?
As the global COVID-19 pandemic has progressed, so too have efforts to develop, manufacture, ...
Understanding Payer Views of Preventive Care
In the past decade, advances in technology and progress in drug innovation have led ...
Top Takeaways from this Year’s CBI Coupon & Copay Forum
At CBI’s eighth annual Coupon & Copay Forum in October, industry experts gathered virtually ...
Expect Amazon to Accelerate its Healthcare Positioning in Three Key Areas
In September 2019, we discussed the definition and impact of the “Amazon Effect” in ...
From Supplier to Public Health Player: The Changing Role of Biopharma Companies
Cell and gene therapies, collectively termed Advanced Therapy Medicinal Products (ATMPs) in the EU, ...
Physician Opinions About “Fair” Prices Vary for Certain Therapies
As the cost of pharmaceutical and biotechnology therapies continues to rise, concern about the ...
First Fill Buy Downs: Maximizing Return in the Face of Prior Authorization
There is no question that prior authorization (PA) requirements around prescribed branded and specialty ...
The Unintended Consequences Behind Gilead’s Remdesivir Pricing Announcement
At the end of June, Gilead announced its long-awaited pricing strategy for remdesivir, which ...
The Ever-Evolving Remote Patient Monitoring Reimbursement Landscape
The urgency of the COVID-19 pandemic has illustrated how essential telehealth services are to ...
Value-Based Healthcare—Demonstrating Value in an Era of Increased Scrutiny and Accountability
Value-based care, value-based contracting, outcomes-based contracting, risk-based contracting—the emergence of these strategies have left ...
Small Drug Features May Have Big Value in the COVID World
When I was an access decision maker at a leading pharmacy benefit manager (PBM), ...
